利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1090 条记录 (耗时 0.046 秒)

    Inhibitors of INV(16) leukemia
    7.
    发明授权
    Inhibitors of INV(16) leukemia 有权

    公开(公告)号：US09926290B2

    公开(公告)日：2018-03-27

    申请号：US14967568

    申请日：2015-12-14

    申请人： University of Virginia Patent Foundation

    发明人： John H. Bushweller ,  Jolanta Grembecka ,  Anuradha Illendula ,  Lauren Mishra

    IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D235/18

    CPC分类号： C07D401/04 ,  C07D235/18 ,  C07D401/14 ,  C07D405/04

    摘要： This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (AML). The inv(16) fusion results in expression of the CBFβ-SMMHC fusion protein in the blood cells of afflicted patients. The present invention provides compounds which inhibit the function of both CBFβ and the CBFβ-SMMHC fusion. These compounds block the growth of an inv(16) leukemia cell line as well as increase its apoptosis, while showing minimal effects against non inv(16) cell lines. As a mechanism to develop inhibitors with selectivity for the CBFβ-SMMHC fusion protein, the present invention further provides dimeric derivatives of these compounds which show both increased potency as well as selectivity for CBFβ-SMMHC. These compounds show potent inhibition of an inv(16) leukemia cell line with minimal effects on non inv(16) cell lines. Analysis of the pharmacokinetics of the developed compounds has made it possible to improve the lifetime of the compound in the plasma of mice to a level commensurate with long-term treatment.